Marpai, Inc. (MRAI)
OTCMKTS: MRAI · Delayed Price · USD
0.830
+0.130 (18.57%)
Jul 2, 2024, 11:49 AM EDT - Market closed
Company Description
Marpai, Inc., a technology-driven healthcare payer, focuses on providing services to the self-insured employer market in the United States and Israel.
The company offers ancillary services, such as care management, case management, actuarial services, bill review and cost containment services.
Marpai, Inc. was incorporated in 2021 and is based in Tampa, Florida.
Marpai, Inc.
Country | United States |
Founded | 2019 |
IPO Date | Oct 27, 2021 |
Industry | Healthcare Plans |
Sector | Healthcare |
Employees | 162 |
CEO | Damien Francis Lamendola |
Contact Details
Address: 615 Channelside Drive, Suite 207 Tampa, Florida 33602 United States | |
Phone | 646-303-3483 |
Website | marpaihealth.com |
Stock Details
Ticker Symbol | MRAI |
Exchange | OTCMKTS |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $4.00 |
CIK Code | 0001844392 |
CUSIP Number | 571354109 |
ISIN Number | US5713542083 |
SIC Code | 8090 |
Key Executives
Name | Position |
---|---|
Damien Francis Lamendola | Chief Executive Officer and Director |
Steve Johnson | Chief Financial Officer and Company Secretary |
John Powers | President and Chief Operating Officer |
Dr. Eli David | Co-Founder and Chief Science Advisor |
Pamela Burns | Vice President of Enterprise Sales |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jun 25, 2024 | 8-K | Current Report |
Jun 12, 2024 | EFFECT | Notice of Effectiveness |
Jun 3, 2024 | 25-NSE | Filing |
May 30, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
May 29, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
May 29, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
May 29, 2024 | 144 | Filing |
May 24, 2024 | 8-K | Current Report |
May 22, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
May 15, 2024 | 144 | Filing |